A meta-analysis on the preadmission use of DPP-4 inhibitors and risk of a fatal or severe course of illness in patients with COVID-19.

Kow, Chia Siang; Hasan, Syed Shahzad

Kow, Chia Siang; Hasan, Syed Shahzad.

Kow CS; School of Postgraduate Studies, International Medical University, No. 126, Jalan Jalil Perkasa 19, Bukit Jalil, 57000 Kuala Lumpur, Malaysia. Electronic address: chiasiang_93@hotmail.com.
Hasan SS; Department of Pharmacy, University of Huddersfield, HD1 3DH Queensgate, Huddersfield, United Kingdom; School of Biomedical Sciences & Pharmacy, University of Newcastle, University Drive, Callaghan, NSW 2308, Australia.

Therapie ; 76(4): 361-364, 2021.

Article in English | MEDLINE | ID: covidwho-1349598

Subject(s)

COVID-19; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidase IV Inhibitors/adverse effects; Humans; Hypoglycemic Agents; SARS-CoV-2

Keywords

Covid-19; DPP-4 inhibitors; Mortality

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Dipeptidyl-Peptidase IV Inhibitors / COVID-19 Type of study: Prognostic study / Reviews Limits: Humans Language: English Journal: Therapie Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google